Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent